Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intrathecal ALN-5288 in adults with Alzheimer's disease
NL-OMON58807Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALN-5288 in Alzheimer's disease (AD) (3 arms), sponsored by Alnylam Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
ALN-5288
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON58807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58807.